Literature DB >> 2434950

Partly native epitopes are already present on early intermediates in the folding of tryptophan synthase.

S Blond, M Goldberg.   

Abstract

Two monoclonal antibodies directed against the native beta 2 subunit of Escherichia coli tryptophan synthase [L-serine hydro-lyase (adding indoleglycerol-phosphate), EC 4.2.1.20], one recognizing the C-terminal F1 domain and the other the N-terminal F2 domain, were used to detect immunoreactive intermediates in the folding of the protein. For that purpose, the association of the monoclonal antibodies with either the beta 2 subunit or its isolated domains was studied by using fluorescence energy transfer between tryptophan residues of the antibodies and a dansyl group covalently linked to the antigen. It is shown that the association of both monoclonal antibodies with the antigen occurs within a few seconds after initiation of the renaturation, whereas complete refolding of the beta 2 subunit requires several minutes under the same experimental conditions. Thus, immunoreactive intermediates appear to be formed at an early stage of the folding process. While the isolated F1 domain alone is able to rapidly refold into a conformational intermediate already well recognized by the anti-native-beta 2 antibody, it cannot, in the absence of the F2 domain, reach its native conformation. However, its association with the anti-native-beta 2 antibody induces a structural change of F1 that brings it closer to the conformation it normally adopts when interacting with F2 inside the native beta 2 subunit.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2434950      PMCID: PMC304383          DOI: 10.1073/pnas.84.5.1147

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  Isolation and characterization of independently folding regions of the beta chain of Escherichia coli tryptophan synthetase.

Authors:  A Högberg-Raibaud; M E Goldberg
Journal:  Biochemistry       Date:  1977-09-06       Impact factor: 3.162

3.  An immunologic approach to the conformational equilibria of polypeptides.

Authors:  D H Sachs; A N Schechter; A Eastlake; C B Anfinsen
Journal:  Proc Natl Acad Sci U S A       Date:  1972-12       Impact factor: 11.205

4.  Synthesis and characterization of two fluorescent sulfhydryl reagents.

Authors:  E N Hudson; G Weber
Journal:  Biochemistry       Date:  1973-10-09       Impact factor: 3.162

5.  Purification and properties of the B component of Escherichia coli tryptophan synthetase.

Authors:  D A Wilson; I P Crawford
Journal:  J Biol Chem       Date:  1965-12       Impact factor: 5.157

6.  Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay.

Authors:  B Friguet; A F Chaffotte; L Djavadi-Ohaniance; M E Goldberg
Journal:  J Immunol Methods       Date:  1985-03-18       Impact factor: 2.303

Review 7.  Folding of protein fragments.

Authors:  D B Wetlaufer
Journal:  Adv Protein Chem       Date:  1981

Review 8.  Specific intermediates in the folding reactions of small proteins and the mechanism of protein folding.

Authors:  P S Kim; R L Baldwin
Journal:  Annu Rev Biochem       Date:  1982       Impact factor: 23.643

9.  Kinetics of renaturation and self-assembly of intermediates on the pathway of folding of the beta 2-subunit of Escherichia coli tryptophan-synthetase.

Authors:  C R Zetina; M E Goldberg
Journal:  J Mol Biol       Date:  1982-05-05       Impact factor: 5.469

Review 10.  The anatomy and taxonomy of protein structure.

Authors:  J S Richardson
Journal:  Adv Protein Chem       Date:  1981
View more
  10 in total

1.  Antibody-detected folding: kinetics of surface epitope formation are distinct from other folding phases.

Authors:  C S Raman; R Jemmerson; B T Nall
Journal:  Protein Sci       Date:  2000-01       Impact factor: 6.725

2.  Kinetic studies of the refolding of yeast phosphoglycerate kinase: comparison with the isolated engineered domains.

Authors:  D Missiakas; J M Betton; A Chaffotte; P Minard; J M Yon
Journal:  Protein Sci       Date:  1992-11       Impact factor: 6.725

3.  Conformation of P22 tailspike folding and aggregation intermediates probed by monoclonal antibodies.

Authors:  M A Speed; T Morshead; D I Wang; J King
Journal:  Protein Sci       Date:  1997-01       Impact factor: 6.725

4.  Dominant negative inhibition by fragments of a monomeric enzyme.

Authors:  J E Michaels; P Schimmel; K Shiba; W T Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

5.  Immunological lesions in human uracil DNA glycosylase: association with Bloom syndrome.

Authors:  G Seal; K Brech; S J Karp; B L Cool; M A Sirover
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

6.  Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

Authors:  B Solomon; R Koppel; D Frankel; E Hanan-Aharon
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

Review 7.  Protein folding dynamics: the diffusion-collision model and experimental data.

Authors:  M Karplus; D L Weaver
Journal:  Protein Sci       Date:  1994-04       Impact factor: 6.725

8.  Conformation-dependent cleavage of staphylococcal nuclease with a disulfide-linked iron chelate.

Authors:  M R Ermácora; J M Delfino; B Cuenoud; A Schepartz; R O Fox
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

9.  Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide.

Authors:  B Solomon; R Koppel; E Hanan; T Katzav
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

10.  Immunological approach for the treatment of Alzheimer's disease.

Authors:  Beka Solomon
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 2.866

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.